OTCPK:NTIL.F

Stock Analysis Report

Executive Summary

Neurotech International Limited engages in the research, design, development, and manufacture of medical devices in Australia.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Risks

  • Neurotech International is not covered by any analysts.

Share Price & News

How has Neurotech International's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:NTIL.F

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

n/a

OTCPK:NTIL.F

8.7%

US Medical Equipment

1.7%

US Market

No trading data on NTIL.F.

No trading data on NTIL.F.


Share holder returns

NTIL.FIndustryMarket
7 Day0%-1.2%1.2%
30 Day0%1.4%4.9%
90 Day0%4.8%3.7%
1 Yearn/a9.6%8.7%3.9%1.7%
3 Yearn/a70.8%65.5%47.2%37.7%
5 Yearn/a130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is Neurotech International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Neurotech International undervalued based on future cash flows and its price relative to the stock market?

0.86x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Neurotech International to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Neurotech International to establish if it is available at substantial discount.


Price Based on Earnings

Neurotech International is loss making, we can't compare its value to the US Medical Equipment industry average.

Neurotech International is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Neurotech International, we can't assess if its growth is good value.


Price Based on Value of Assets

Neurotech International is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Neurotech International expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Neurotech International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of NTIL.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Neurotech International's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Neurotech International performed over the past 5 years?

0.6%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Neurotech International does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Neurotech International's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Neurotech International's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Neurotech International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Neurotech International has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Neurotech International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Neurotech International's financial position?


Financial Position Analysis

Neurotech International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Neurotech International has no long term commitments.


Debt to Equity History and Analysis

Neurotech International's level of debt (1.3%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Neurotech International's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 28.7x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Neurotech International has less than a year of cash runway based on current free cash flow.

Neurotech International has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.3% each year.


Next Steps

Dividend

What is Neurotech International's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Neurotech International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Neurotech International's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Neurotech International has not reported any payouts.

Unable to verify if Neurotech International's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Neurotech International has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Neurotech International's salary, the management and board of directors tenure and is there insider trading?

0.7yrs

Average management tenure


CEO

Peter James Griffiths (55yo)

0.7yrs

Tenure

AU$106,126

Compensation

Mr. Peter James Lawrence Griffiths has been the Chief Executive Officer and Managing Director at Neurotech International Limited since November 26, 2018. Mr. Griffiths a Senior Advisor at Bridge Growth Par ...


CEO Compensation Analysis

Peter James's remuneration is lower than average for companies of similar size in United States of America.

Peter James's compensation has increased whilst company is loss making.


Management Age and Tenure

0.7yrs

Average Tenure

The average tenure for the Neurotech International management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.5yrs

Average Tenure

The average tenure for the Neurotech International board of directors is less than 3 years, this suggests a new board.


Insider Trading

Neurotech International individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellAU$38,07503 Jun 19
Adrian Trevisan
EntityIndividual
Shares3,135,011
Max PriceAU$0.012
SellAU$137,29303 Jun 19
Adrian Trevisan
EntityIndividual
Shares15,870,688
Max PriceAU$0.0095
BuyAU$80,66228 Feb 19
Pyxis Holdings Pty Ltd
EntityCompany
Shares3,749,999
Max PriceAU$0.022
SellAU$9,16712 Nov 18
Adrian Trevisan
EntityIndividual
Shares190,832
Max PriceAU$0.048

Ownership Breakdown


Management Team

  • Peter James Griffiths (55yo)

    Deputy Chairman

    • Tenure: 0.7yrs
    • Compensation: AU$106.13k
  • Fleur Hudson

    Company Secretary

    • Tenure: 0yrs
  • Erlyn Dale

    Company Secretary

    • Tenure: 0.2yrs
  • Emanuela Russo

    Chief Scientific Officer & Member of Scientific Advisory Board

    • Tenure: 0yrs

Board Members

  • Peter James Griffiths (55yo)

    Deputy Chairman

    • Tenure: 0.7yrs
    • Compensation: AU$106.13k
  • Evian Gordon

    Member of Scientific Advisory Board

    • Tenure: 0.8yrs
  • Winton Willesee

    Non-Executive Director

    • Tenure: 0.2yrs
  • Mark Davies

    Chairman

    • Tenure: 0.2yrs
  • David Cantor

    Chairman of Scientific Advisory Board & Non-Executive Director

    • Tenure: 0yrs
  • Emanuela Russo

    Chief Scientific Officer & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Tanju Surmeli

    Member of Scientific Advisory Board

    • Tenure: 0.8yrs

Company Information

Neurotech International Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Neurotech International Limited
  • Ticker: NTIL.F
  • Exchange: OTCPK
  • Founded: 2016
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$2.715m
  • Listing Market Cap: AU$1.891m
  • Shares outstanding: 135.74m
  • Website: https://www.neurotechinternational.com

Location

  • Neurotech International Limited
  • 145 Stirling Highway
  • Suite 5 CPC
  • Nedlands
  • Western Australia
  • 6009
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NTIASX (Australian Securities Exchange)YesOrdinary SharesAUAUDNov 2016
NTICHIA (Chi-X Australia)YesOrdinary SharesAUAUDNov 2016
NTIL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 2016

Biography

Neurotech International Limited engages in the research, design, development, and manufacture of medical devices in Australia. Its product is Mente Autism, a portable electroencephalogram medical device th ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/07 01:05
End of Day Share Price2019/04/08 00:00
Earnings2018/12/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.